Ying Zhou

Prof. Dr. Ying Zhou


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
CLChang Liu
Chang Liu
ZYZhigang Yin
Zhigang Yin
TFTingting Feng
Tingting Feng
MZMin Zhang
Min Zhang
ZZZhi Zhou
Zhi Zhou
YZYing Zhou
Ying Zhou

2 October 2020 in Organic & Biomolecular Chemistry
Verified
Journal Article
Closed access
PDF file
YSYang Shi
Yang Shi
BPBo-Wen Pan
Bo-Wen Pan
YZYing Zhou
Ying Zhou
JZJian Zhou
Jian Zhou
YLYun-Lin Liu
Yun-Lin Liu
FZFeng Zhou
Feng Zhou
This review summarizes the advances in catalytic enantioselective reactions using CO 2 as a C1 synthon, introduces strategies and discusses advantages and limitations, highlights the application, and outlines the synthetic opportunities.

10 December 2024 in RSC Advances
Verified
Journal Article
Open access
PDF file
LZLing Rong Zeng
Ling Rong Zeng
BPBo Wen Pan
Bo Wen Pan
JCJuan Cai
Juan Cai
LLLi Juan Liu
Li Juan Liu
ZDZhang Chao Dong
Zhang Chao Dong
YSYang Shi
Yang Shi
Pentacyclic triterpenoids, as important representatives of natural products, have garnered widespread attention due to their diverse biological activities, including anti-inflammatory, antiviral, and antitumor effects. Oleanolic acid (OA), betulinic acid (BA), ursolic acid (UA), triptolide, and glycyrrhetinic acid (GA) are typical examples of pentacyclic triterpenoids. Despite their significant biological activities, their poor water solubility and low bioavailability have limited further development and application. In recent years, researchers have developed a series of derivatives with enhanced biological activities and improved drug properties through structural modifications of these compounds, particularly achieving notable progress in the field of antitumor therapy. This review summarizes recent advances in the structural modification of pentacyclic triterpenoids and explores their promising applications in the development of antitumor, antiviral, and other therapeutic agents.

10 August 2021 in Chemical Communications
Verified
Journal Article
Closed access
PDF file
CLChuan-Wen Lei
Chuan-Wen Lei
BMBo-Shuai Mu
Bo-Shuai Mu
FZFeng Zhou
Feng Zhou
JYJin-Sheng Yu
Jin-Sheng Yu
YZYing Zhou
Ying Zhou
JZJian Zhou
Jian Zhou
This feature article aims to summarize the exciting advances in organocatalytic enantioselective reactions involving prochiral carbocationic intermediates.

Verified
Journal Article
Open access
PDF file
XZXiuliang Zhu
Xiuliang Zhu
NLNan Lu
Nan Lu
YZYing Zhou
Ying Zhou
SXShaoyan Xuan
Shaoyan Xuan
JZJiaojiao Zhang
Jiaojiao Zhang
ZWZuhua Wang
Zuhua Wang
Pancreatic cancer is a concealed and highly malignant tumor, and its early diagnosis plays an increasingly weighty role during the course of cancer treatment. In this study, we developed a polymeric magnetic resonance imaging (MRI) nanoplatform for MRI contrast agents. To improve tumor-targeting delivery of MRI contrast agents, we employed a pancreatic cancer targeting CKAAKN peptide to prepare a peptide-functionalized amphiphilic hyaluronic acid–vitamin E succinate polymer (CKAAKN–HA–VES) for delivering ultra-small superparamagnetic iron oxide (USPIO), namely, CKAAKN–HA–VES@USPIO. With the modification of the CKAAKN peptide, CKAAKN–HA–VES@USPIO could specifically internalize into CKAAKN-positive BxPC-3 cells. The CKAAKN–HA–VES@USPIO nanoparticles presented a more specific accumulation into pancreatic cancer cells than normal pancreatic cells, and an obvious decrease in signal intensity was observed in CKAAKN-positive BxPC-3 cells, compared with CKAAKN-negative HPDE6-C7 cells and non-targeting HA–VES@USPIO nanoparticles. The results demonstrated that our polymeric MRI nanoplatform could selectively internalize into CKAAKN-positive pancreatic cancer cells by the specific binding of CKAAKN peptide with pancreatic cancer cell membrane receptors, which provided a novel polymeric MRI contrast agent with high specificity for pancreatic cancer diagnosis, and makes it a very promising candidate for magnetic resonance imaging contrast enhancement.

1 November 2020 in Fitoterapia
Verified
Journal Article
Closed access
XHXin-Yue Hu
Xin-Yue Hu
XWXin Wei
Xin Wei
YZYong-Qiang Zhou
Yong-Qiang Zhou
XLXiong-Wei Liu
Xiong-Wei Liu
JLJia-Xin Li
Jia-Xin Li
YZYing Zhou
Ying Zhou